Based on the Prothena Corporation plc stock forecasts from 4 analysts, the average analyst target price for Prothena Corporation plc is USD 62.00 over the next 12 months. Prothena Corporation plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Prothena Corporation plc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Prothena Corporation plc’s stock price was USD 58.00. Prothena Corporation plc’s stock price has changed by +85.24% over the past week, +107.29% over the past month and -19.21% over the last year.

2. Page 1 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | NSD | Common Stock
Values as of 28th Sep, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Last Close
USD 58.00
Change
+27.07(+87.52%)
Market Cap
USD 1.36B
1 Yr Capital Gain
-18.09%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-18.09%
Earning Growth (5 yr)
141.83%
Average Target Price
62.00(+6.90% )
Average Analyst
Rating
Strong Buy
Fundamental
Analysis
Slightly Bullish
Our view of the stock is Slightly Bullish with a score of 6.7 out of 10, where 0 is very bearish and 10 very bullish
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in
the long run.
What to not like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering
to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are
considering to buy.

3. Page 3 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
PRTA
Prothena Corporation plc
-19.2% 0 -19.2%
QQQ
Invesco QQQ Trust
-22.2% +0.4% -21.8%
Company Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening
diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III
clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the
treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005,
which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the
treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation
plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop
and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.
The company was founded in 2012 and is based in Dublin, Ireland.

4. Page 4 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.prothena.com
Address
77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Fiscal Year End
December
Employees
82
Technical Indicators
Value Value
Beta 1.32 52 Week High 74.32
Short Ratio 8.47 52 Week Low 21.06
Shorted Shares 2,464,097 200 Day Moving Average 33.00
Shorted Shares Previous Month 2,684,256 50 Day Moving Average 30.26
Shares Held By Insiders 547.10% Short Percentage 3.00%
Shares Held by Institutions 94.32 Dividend Yield N/A

5. Page 5 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain 17.41% -50.3% 91% -27.0% 95%
Dividend Return N/A 6.1% N/A 1.7% N/A
Total Return 17.41% -50.0% 91% -25.9% 95%
Trailing 12 Months
Capital Gain -18.09% -63.7% 83% -29.0% 60%
Dividend Return N/A 7.8% N/A 2.4% N/A
Total Return -18.09% -63.7% 83% -27.2% 58%
Trailing 5 Years
Capital Gain -10.45% -65.3% 72% -8.2% 48%
Dividend Return N/A 13.8% N/A 10.5% N/A
Total Return -10.45% -63.2% 71% 2.3% 41%
Average Annual (5 Year Horizon)
Capital Gain 59.38% -7.8% 89% 0.2% 92%
Dividend Return N/A 2.3% N/A 1.8% N/A
Total Return 59.38% -7.8% 89% 0.7% 92%
Risk Return Profile
Volatility (Standard
Deviation)
154.67% 42.9% 10% 33.4% 7%
Risk Adjusted Return 38.39% N/A 84% 10.9% 73%
Market Capitalization 1.36B 0.12B 89% 0.28B 80%

6. Page 6 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio 19.7 6.4 27% 16.8 44%
pbratio 3.5 1.8 29% 1.4 23%
pcfratio 14.7 -2.7 4% -1.2 16%
pfcfratio 543.5 -0.8 0% 0.0 0%
Management Effectiveness
retequity -0.42% -58.1% 93% -7.0% 56%
retinvcap 20.62% -52.4% 90% -1.5% 86%
retass -0.64% -26.8% 94% -0.9% 52%
debtequityratio N/A 19.8% N/A 30.2% N/A
Technical Ratios
yield N/A 1.9% N/A 3.0% N/A
sratio 8.47 3.79 24% 2.67 14%
spercent 15.09% 3.4% 10% 2.3% 9%
beta 1.32 1.16 39% 1.06 31%

7. Page 7 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Maintains RBC Royalbank Outperform USD 45 » USD 52 2022-09-28
Upgrades Bank of America Buy 2022-09-28
Upgraded by Bank of America Securities Neutral » Buy USD 45 » USD 65 2022-09-28
Target Raised by JMP Securities USD 50 » USD 81 2022-09-28
Maintains JMP Securities Market Outperform USD 77 » USD 50 2022-05-25
Target Lowered by Citigroup USD 87 » USD 73 2022-02-18
Initiated by JMP Securities Outperform USD 77 2021-11-19
Target Raised by RBC Royalbank Outperform USD 59 » USD 82 2021-09-30
Target Raised by Oppenheimer Holdings Outperform USD 90 » USD 100 2021-09-27
Initiated by Fox Advisors Overweight USD 14 2021-09-20
Target Raised by Cantor Fitzgerald Securities Overweight USD 70 » USD 103 2021-09-17
Target Raised by Oppenheimer Holdings Outperform USD 82 » USD 90 2021-09-14
Maintains Oppenheimer Holdings Outperform USD 76 » USD 82 2021-08-09
Maintains RBC Royalbank Outperform USD 50 » USD 59 2021-07-19
Maintains Citigroup Buy USD 57 » USD 72 2021-07-13
Maintains Oppenheimer Holdings Outperform USD 54 » USD 76 2021-07-13
Maintains HC Wainwright Buy USD 58 » USD 75 2021-07-13
Upgraded by Bank of America Securities Underperform » Neutral USD 12 » USD 49 2021-06-18
Target Raised by RBC Royalbank Outperform USD 28 » USD 50 2021-06-11
Reiterated by HC Wainwright Buy USD 33 » USD 58 2021-06-10
Target Raised by Oppenheimer Holdings Positive » Outperform USD 45 » USD 54 2021-06-08
Target Raised by Cantor Fitzgerald Securities Overweight USD 43 » USD 62 2021-06-08
Target Raised by Oppenheimer Holdings Outperform USD 40 » USD 45 2021-06-01
Initiates Coverage On Citigroup Buy USD 39 2021-05-26
Target Raised by Oppenheimer Holdings Outperform USD 35 » USD 40 2021-05-12

8. Page 8 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Annual Financial (USD)

9. Page 9 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Quarterly Financial (USD)

10. Page 10 of 10 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
PRTA:NSD (Prothena Corporation plc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 29th September, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc +10.41 (+1.5%) USD 74.83B
VRTX Vertex Pharmaceuticals Inc +7.67 (+2.7%) USD 72.69B
MRNA Moderna Inc -0.08 (-0.1%) USD 47.82B
ALXN Alexion Pharmaceuticals Inc N/A USD 40.34B
BNTX BioNTech SE +3.49 (+2.7%) USD 30.98B
RPRX Royalty Pharma Plc +1.03 (+2.6%) USD 27.26B
SGEN Seagen Inc +2.37 (+1.8%) USD 24.95B
ALNY Alnylam Pharmaceuticals Inc +8.15 (+4.0%) USD 24.32B
GMAB Genmab AS +0.82 (+2.6%) USD 21.66B
IMMU Immunomedics, Inc N/A USD 20.31B
ETFs Containing PRTA
Symbol Company Name Weight Mer Price(Change) Market Cap
UNIC:LSE Lyxor Index Fund - Lyxor MSCI .. 0.00 % 0.00 % +0.08 (+0.8%) USD 0.18B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%